<div id="readability-page-1"><div><ul> <li>Grand Pharmaceutical Group reported its 2025 results with sales rising to HK$12,283.27 million while net income and EPS fell sharply, and it announced a lower annual dividend alongside guidance citing investment fair value losses and pressure from centralized drug procurement.</li> <li>At the same time, the group advanced its innovation pipeline with Chinese approval to commercialize GPN01768 for Demodex blepharitis and Phase II clearance for migraine candidate GPN01020, underlining a push to offset pricing headwinds through new ophthalmology and neurology treatments.</li> <li>We’ll now examine how Grand Pharmaceutical’s weaker 2025 profit but expanding ophthalmic and migraine portfolios shape its investment narrative for investors.</li> </ul><p>Outshine the giants: these 22 early-stage AI stocks could fund your retirement.</p><h2>What Is Grand Pharmaceutical Group's Investment Narrative?</h2><p>To stay invested in Grand Pharmaceutical now, you really have to believe that its expanding ophthalmology and neurology pipeline can eventually matter more than the current profit squeeze. The 2025 results confirmed what the March guidance hinted at: higher sales but much slimmer margins, hit by fair value losses and centralized procurement, and now a lower HK$0.169 dividend signals management is prioritizing reinvestment over cash returns. At the same time, the NMPA approval of GPN01768 for Demodex blepharitis and Phase II clearance for migraine candidate GPN01020 bring nearer term product catalysts into focus, even if they will not quickly offset the drag from pricing and heavier marketing spend. For now, the key tension in the story is between margin pressure and the promise of an innovation-driven product mix.</p><p> However, investors should be aware of how vulnerable earnings remain to further pricing and investment swings.  Grand Pharmaceutical Group's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/639e7f90-1c43-4e2e-adb8-074b9a24cc0b/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/639e7f90-1c43-4e2e-adb8-074b9a24cc0b/chart/quote-price"/><figcaption>SEHK:512 1-Year Stock Price Chart</figcaption></figure><p> Three Simply Wall St Community fair value estimates, from HK$11.25 to HK$22.44, underline how differently people see Grand Pharmaceutical’s upside. Set against margin compression and dividend cuts, that spread invites you to weigh pipeline hopes against current earnings pressure.</p><p>Explore 3 other fair value estimates on Grand Pharmaceutical Group - why the stock might be worth over 3x more than the current price!</p><h2>The Verdict Is Yours</h2><p>Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Grand Pharmaceutical Group research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Grand Pharmaceutical Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Grand Pharmaceutical Group's overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:</p><ul><li>The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.</li><li>Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

520880

00512

513120

520690

159506

159316

捍宇医疗

520500

<p>Grand Pharmaceutical Group's shares rose 9.7% following its mixed 2025 results, which showed increased sales of HK$12,283.27 million but a significant drop in net income and EPS. The company announced a lower annual dividend and highlighted challenges from centralized drug procurement. However, it received approval for new drugs, GPN01768 and GPN01020, aimed at treating Demodex blepharitis and migraines, respectively. Investors are weighing the potential of these innovations against current profit pressures and margin compression.</p>

Simplywall

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GRANDPHARMA

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Why Grand Pharmaceutical Group (SEHK:512) Is Up 9.7% After Mixed 2025 Results And New Drug Milestones